

Beovu® (brolucizumab-dblI)

When requesting Beovu® (brolucizumab-dblI), the individual requiring treatment must be diagnosed with the following FDA-approved indication or the approved off-label compendial use and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indication

Beovu is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

Approved Off-Label Compendial Uses

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, choroidal neovascular conditions)

Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Beovu is administered by or under the supervision of an ophthalmologist

Approval duration: 12 months

Dosing Recommendation

Beovu is administered by intravitreal injection.

For neovascular age-related macular degeneration and other neovascular diseases of the eye: The recommended dose of Beovu is 6 mg monthly for the first three doses, followed by one dose of 6 mg every 8-12 weeks.

For diabetic macular edema: The recommended dose of Beovu is 6 mg once every 39 to 45 days for the first five doses, followed by one dose of 6 mg every 8-12 weeks.

References

1. Beovu® [prescribing information]. Hanover, NJ: Novartis Pharmaceuticals; May 2022.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.